Related Experiment Video
Updated: Sep 10, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia
Khalil Saleh1, Ahmadreza Arbab2, Nadine Khalife3
1International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.
Abstract:
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells. Multiple new classes of drugs had been approved for the management of patients with CLL, reshaping the treatment paradigm. The most important classes are Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. Both of them are approved as a first-line treatment in patients with CLL requiring treatment. The role of BTK and BCL-2 in the signaling pathways of the TME is very important. The aim of this review is to summarize the major components of the TME and the available data regarding targeted therapies in CLL.
Related Concept Videos
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

